As the post-pandemic world of work continues to evolve, so do recruiters’ strategies and tools for finding and engaging top talent. In 2023, we are seeing these seven trends:1. Employer branding is becoming an increasingly important factor in the recruitment…
HOME > BUSINESS
BUSINESS
- Eisai to Accelerate Clinical Development with Milestone Payments, Signs Agreement on PIII Trials for Lenvatinib
September 8, 2011
- Eplerenone significantly Reduces Cardiovascular Death in High-Risk CHF Patients: Pfizer
September 7, 2011
- MTPC to Reorganize Its Subsidiary
September 7, 2011
- ASKA to Initiate Transparency GL Project on Full Scale in October
September 7, 2011
- Tarceva Approved for 1st-line in NSCLC: Roche
September 6, 2011
- Ogasawara to Become President, Ogawa to Step Down: RDKK
September 6, 2011
- Chugai Starts US-Japan PI Trials of Multiple In- Licenced Compounds from Roche
September 6, 2011
- Janssen Adds Precautions for CONCERTA for Administering to Patients Over 18
September 5, 2011
- Eisai Decides to Discontinue Development of Pariet Extended-Release Preparation
September 5, 2011
- Otsuka to Launch TS-1 in Europe in 2nd Quarter of 2012
September 5, 2011
- Takeda to Construct New Production Facilities for Flu Vaccines at Its Hikari Plant
September 5, 2011
- Kitasato Daiichi Sankyo Vaccine to Construct New-type Flu Vaccine Manufacturing Facilities
September 5, 2011
- KIX-Medica Increases Total Capacity
September 5, 2011
- BMKK Encourages Its MRs to Use Hybrid Cars
September 5, 2011
- Otsuka to Create Special Subsidiary for Employees with Disabilities
September 5, 2011
- Astellas Files for Mirabegron in US and Europe
September 5, 2011
- NDA for Lurasidone Accepted in Canada: DSP
September 5, 2011
- Large-scale Users Should Accept “Unit Price-based, By-product Deals”: Mr Bessho of JPWA
September 5, 2011
- Over 10% of Pharmacists Switched to Generic Actos in Just 1 Week: Nextit
September 5, 2011
- CSD Report Highlights Growing Importance of Biopharmaceutical Market in 2010
September 5, 2011
ページ
Novo Nordisk’s weight-loss medication Wegovy (semaglutide) was approved in Japan in March. While it skipped the May round of reimbursement listing, physicians eagerly await the arrival of what would be the first new obesity drug in three decades. Other companies…
Japan’s health ministry on April 27 presented an outline of a report to be compiled next month by its key…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…